Ecallantide
A 60-amino-acid protein engineered by phage display from a human clotting inhibitor, injected to stop hereditary angioedema attacks. It carries a boxed warning for anaphylaxis in 4% of patients, which is why it must be given by a clinician, why Europe never approved it, and why newer drugs have largely replaced it.
Ecallantide is an injection given in a clinic or hospital to stop a hereditary angioedema attack — sudden dangerous swelling caused by a chemical called bradykinin. It blocks the enzyme that makes that chemical. It works, but about 4 in 100 people have a severe allergic reaction to it, which looks confusingly like the attack itself, so only a healthcare professional can give it. Newer treatments that people can take themselves, including a pill, have mostly replaced it.
What is Ecallantide?
Ecallantide is a recombinant 60-amino-acid protein that blocks plasma kallikrein, the enzyme that cuts high-molecular-weight kininogen to release bradykinin. It is sold as Kalbitor and was approved by the FDA on 1 December 2009 for acute attacks of hereditary angioedema in patients aged 12 and over. Hereditary angioedema is caused by deficient or dysfunctional C1-esterase inhibitor, which normally restrains plasma kallikrein; without that brake, attacks flood tissue with bradykinin and produce swelling that antihistamines and adrenaline cannot touch. Ecallantide inhibits the enzyme directly, with an inhibition constant of 25 picomolar. It is produced in Pichia pastoris yeast and given as three separate 10 mg subcutaneous injections totalling 30 mg — and, unlike every other on-demand treatment for this disease, it must be administered by a healthcare professional rather than the patient.
What Ecallantide Is Investigated For
Ecallantide has one approved use, a clean pair of trials behind it, and a position in practice that has steadily eroded. The two phase 3 studies, EDEMA3 and EDEMA4, both met their primary endpoints using patient-reported scales — in EDEMA3 the median treatment outcome score at four hours was 50.0 on ecallantide against 0.0 on placebo, and in EDEMA4 the mean symptom complex severity score fell 0.8 versus 0.4. The less-quoted result from EDEMA3 is the one a patient would care about most: estimated time to significant improvement was 165 minutes on drug versus more than 240 on placebo, and that comparison did not reach significance (p=0.14). Outside hereditary angioedema the record is negative. A randomised trial in ACE-inhibitor-induced angioedema found 72% of placebo patients met discharge criteria within six hours against 85–89% across three ecallantide doses, a difference that was not significant, and the study was halted at interim analysis. The drug's trajectory has been shaped less by efficacy than by the 4% anaphylaxis rate: Europe never approved it, the requirement for clinician administration sits awkwardly against guidelines urging patients to treat every attack as early as possible, and since July 2025 an oral plasma kallikrein inhibitor, sebetralstat, has been available for the same indication.
History & Discovery
Ecallantide is a product of phage display, and its history belongs as much to a technology as to a disease. Dyax Corporation was founded in Cambridge, Massachusetts around the display libraries developed by Robert Ladner, whose patents on the method sat alongside the work of George Smith and Gregory Winter that would eventually win the 2018 Nobel Prize in Chemistry. Rather than displaying antibodies, Dyax applied the method to protein scaffolds, and the scaffold chosen here was the first Kunitz domain of human lipoprotein-associated coagulation inhibitor — a compact, disulfide-stabilised serine protease inhibitor fold. The 1996 Biochemistry paper by Markland, Ley and Ladner describes the approach working almost mechanically: one library built around the protease-contact loop was screened against plasma kallikrein and against thrombin, yielding tight and specific inhibitors of kallikrein with picomolar affinities, and demonstrating along the way that a single large combinatorial library could serve as the source for several different targets. The compound entered development as DX-88. It was taken into two indications at once. One was hereditary angioedema; the other was prevention of blood loss in on-pump cardiothoracic surgery, the niche then occupied by aprotinin, another Kunitz-domain inhibitor. The surgical programme did not survive. The angioedema programme produced EDEMA3 and EDEMA4 and reached FDA approval on 1 December 2009, making ecallantide the second on-demand treatment approved in the United States for a disease that had none at all until the year before. Europe went differently. Dyax filed with the EMA in June 2010 and withdrew on 11 November 2011, at day 181, citing an inability to answer the committee's questions — the rate of hypersensitivity reactions, and whether 30 mg was enough in heavier patients. The company said it might resubmit with a higher-strength formulation; it never did. Shire acquired Dyax in 2016, Takeda acquired Shire in 2019, and Kalbitor has passed through both without its label changing in substance. By then the field had moved: guidelines had come to recommend treating every attack as early as possible, home therapy had become the norm, and in July 2025 sebetralstat arrived as an oral inhibitor of the very enzyme ecallantide had been engineered to block.
How It Works
In hereditary angioedema, a missing brake lets an enzyme called plasma kallikrein run unchecked. That enzyme chops a large blood protein and releases bradykinin, a molecule that makes blood vessels leak — which is what produces the sudden, deep swelling of an attack. Ecallantide clamps onto the enzyme and stops it cutting, so bradykinin production halts and the swelling can subside.
Hereditary angioedema is an autosomal dominant disorder caused by mutations in the C1-esterase inhibitor gene on chromosome 11q, producing low levels of C1-INH activity and, characteristically, low C4. C1-INH is the principal endogenous brake on plasma kallikrein as well as a regulator of the classical complement and intrinsic coagulation pathways. When it is deficient, plasma kallikrein activity goes unregulated and cleaves high-molecular-weight kininogen to generate bradykinin in excess. Bradykinin is a potent vasodilator and permeability agent, and it is the mediator responsible for the localised swelling, inflammation and pain of an attack — which is why histamine-directed treatment fails in this disease. Ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein with an inhibition constant of 25 picomolar. It binds the enzyme and blocks its active site, preventing conversion of high-molecular-weight kininogen to bradykinin. The selectivity matters: Kunitz domains inhibit serine proteases as a class, and the engineering problem was obtaining tight binding to plasma kallikrein without inhibiting the many related enzymes that would cause trouble. The molecule itself is a 60-amino-acid, 7,054-dalton protein expressed in Pichia pastoris yeast by recombinant DNA. Its parent scaffold is the first Kunitz domain of human lipoprotein-associated coagulation inhibitor — the protein now usually called tissue factor pathway inhibitor. In a 1996 Biochemistry paper, Markland, Ley and Ladner at Dyax described generating phage-display libraries from that domain, varying five positions near the P1 residue and then nine positions in an expanded library, and selecting against human plasma kallikrein. The best variant from the final library, EPI-K503, had a Ki of 40 picomolar with high specificity. Ecallantide is the product of that lineage, and it belongs to a small group of approved drugs that came out of phage display rather than from immunisation or from natural-product chemistry. The pharmacokinetics are brisk and simple. A single 30 mg subcutaneous dose in healthy subjects reaches a mean peak plasma concentration of 586 ng/mL at two to three hours, with an elimination half-life of 2.0 hours, plasma clearance of 153 mL/min and a volume of distribution of 26.4 L. It is small enough to be eliminated renally and has been demonstrated in the urine of treated subjects. Body weight, age and sex did not significantly affect exposure in population analysis — though the adequacy of a single fixed 30 mg dose across the weight range was one of the questions the CHMP raised during its European review.
Evidence Snapshot
Human Clinical Evidence
Strong for the approved indication, with a clear caveat about what was measured. Two randomised, double-blind, placebo-controlled phase 3 trials — EDEMA3 and EDEMA4 — enrolled 168 patients, 143 of them unique, and both met their primary endpoints on patient-reported severity and outcome scales. An integrated analysis, an open-label continuation study, pooled analyses of laryngeal attacks and of second-dose requirements, and a paediatric series fill in the picture. The limitation is that the endpoints are patient-reported composites rather than objective measures, and that in EDEMA3 the most intuitive endpoint — time to significant improvement — did not reach significance.
Animal / Preclinical
Thin, and that is appropriate for a molecule engineered against a human enzyme whose role in a human genetic disease was already established. The relevant preclinical work is biochemical rather than animal: the phage-display selection and the enzymology establishing picomolar inhibition and selectivity against related serine proteases.
Mechanistic Rationale
Very strong and among the cleanest in therapeutics. The genetic defect is known, the unrestrained enzyme is known, the mediator is known, and blocking the enzyme is a direct intervention on the causal chain rather than a downstream one. The subsequent approval of an oral inhibitor of the same enzyme, and of a C1-inhibitor replacement upstream of it, are independent confirmations that the target is right.
Research Gaps & Open Questions
What the current literature has not yet settled about Ecallantide:
- 01Who develops anaphylaxis, and why. Reactions never occurred on first exposure, implying sensitisation, yet IgE testing against ecallantide and against its Pichia pastoris expression system was not reliably positive in the patients who reacted. Without a predictive test, the 4% rate is an unmanageable risk rather than a screenable one.
- 02Whether 30 mg is the right dose across the weight range. The CHMP raised the question in 2011 and the planned bioequivalence study of a higher-strength formulation was never completed. Population analysis found weight did not significantly affect exposure, but exposure is not the same as adequacy of effect.
- 03Whether it has any specific advantage in laryngeal attacks. These are the attacks that can be fatal and they were 24 of 143 patients in the pivotal programme; the evidence is a pooled, partly open-label analysis rather than a dedicated trial, and no such trial is likely to be run.
- 04What its role is now that an oral inhibitor of the same enzyme exists. Sebetralstat was approved in July 2025 and no comparison with ecallantide has been attempted; an indirect comparison was published against recombinant human C1-INH instead.
- 05Whether any engineered successor is viable. An albumin-fusion version with an extended circulatory half-life has been reported, and a mutated variant redirected to factor XIa for antithrombosis — both academic exercises rather than programmes, but both indications that the scaffold still interests people.
- 06Whether the negative ACE-inhibitor angioedema result reflects the drug or the trial. The study was halted at interim because 72% of placebo patients met discharge criteria within six hours, which suggests the population was too mild to show a difference; the authors explicitly suggested that more severe presentations might still be worth studying.
- 07How it performs in pregnancy, where published guidance derives from a safety review rather than from data in treated pregnancies.
Forms & Administration
Subcutaneous injection only, administered by a healthcare professional. The dose is 30 mg given as three separate 1 mL injections of 10 mg/mL, drawn from three single-use vials using a large-bore needle and then injected through a 27-gauge needle into the skin of the abdomen, thigh or upper arm. The three injections may go into the same or different anatomical areas but must be at least 5 cm apart and away from the site of the attack; there is no requirement to rotate sites. Vials are refrigerated and protected from light, and the solution is preservative-free at approximately pH 7.0. If the attack persists, a second 30 mg dose may be given within 24 hours, following the same instructions. There is no self-administration, autoinjector, intravenous or oral form of this drug.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
30 mg per attack, given as three separate 10 mg (1 mL) subcutaneous injections. A second 30 mg dose may be given within a 24-hour period if the attack persists.
Frequency
On demand, for an acute attack only. Ecallantide is not a prophylactic agent and has no scheduled dosing.
Timing Considerations
Time of day
Whenever an attack occurs
Relative to meals
No relationship to food
Relative to exercise
Not tied to exercise timing.
Guidelines favour treating attacks as early as possible after onset, but with ecallantide the practical constraint is reaching a healthcare professional. Analyses from the EDEMA trials examined response by time to intervention for exactly this reason.
Cycle Length
Not applicable. This is an episodic rescue treatment used when an attack occurs, not a maintenance therapy. Patients with frequent attacks are managed with long-term prophylaxis using different drugs entirely.
Protocol Notes
The administration detail is unusually prescriptive because the whole dose cannot be given in one injection. Each 1 mL vial is drawn up with a large-bore needle, the needle is then changed to a 27-gauge needle suitable for subcutaneous use, and the injection goes into the skin of the abdomen, thigh or upper arm. The procedure repeats for all three vials. The three sites may be in the same anatomical region or different ones, must be at least 5 cm apart, and must be away from the anatomical site of the attack itself. Site rotation is not required. The critical operational point is not the technique but the setting. The boxed warning requires that ecallantide be administered only by a healthcare professional with appropriate medical support to manage both anaphylaxis and hereditary angioedema, and patients must be observed afterwards for a period informed by the trial data, in which all anaphylaxis occurred within the first hour. That requirement is what separates this drug from every other on-demand option in the disease, and it sits in direct tension with the guideline consensus that attacks should be treated as early as possible after onset — since the clock starts when the patient reaches a clinician, not when the attack begins. If a second 30 mg dose is needed within 24 hours, the same instructions apply and the injections may go into the same anatomical sites used for the first.
Ecallantide is a prescription biologic that carries a boxed warning for anaphylaxis and may only be administered by a healthcare professional equipped to manage it. It is approved in the United States only, for acute attacks of hereditary angioedema in patients aged 12 and older. The figures above describe approved practice and are not guidance for anyone to act on independently.
Timeline of Effects
Onset
Within hours, with the honest caveat that the strongest endpoint is the weakest result. Benefit was apparent within two hours of dosing in EDEMA4 and the four-hour endpoints were significant in both pivotal trials. But EDEMA3's estimated time to significant improvement — 165 minutes on drug against more than 240 on placebo — did not reach statistical significance at p=0.14, in a trial of 72 patients. Pharmacokinetics are consistent with rapid action: peak plasma concentration arrives two to three hours after subcutaneous injection, and the enzyme is inhibited at picomolar concentrations.
Peak Effect
The trials measured at four and 24 hours and found improvement maintained across that window. Roughly a quarter to a third of attacks in the pooled programme required a second 30 mg dose within 24 hours, and a dedicated analysis examined who those patients were. Rebound and relapse were also studied specifically and did not emerge as a distinct pattern.
After Discontinuation
There is nothing to discontinue — this is an episodic rescue treatment with a two-hour elimination half-life, and it leaves the body long before the next attack. What it does not do is change the underlying disease: C1-esterase inhibitor deficiency is genetic and permanent, plasma kallikrein activity returns to its unregulated state as soon as the drug clears, and attack frequency is unaffected. Patients whose attacks are frequent enough to need prevention are managed with long-term prophylaxis using entirely different agents.
Monitoring & Measurement
Bloodwork & Labs
- •C4 complement level — characteristically low in hereditary angioedema and the usual first screening test
- •C1-esterase inhibitor antigenic level and functional activity, which distinguish type I from type II disease and confirm the diagnosis before any on-demand drug is prescribed
- •C1q level, used to separate hereditary from acquired C1-INH deficiency, since the acquired form has a different cause and different associations
- •No laboratory marker tracks ecallantide itself or predicts hypersensitivity — IgE testing against the drug and against Pichia pastoris was not reliably positive in patients who had anaphylaxis
Functional & Performance Tests
- •Direct observation for one hour or more after dosing, which is the single most important monitoring step and the reason the drug requires a clinical setting
- •Airway assessment in any attack with laryngeal involvement, independent of which drug is used
- •Mean Symptom Complex Severity score and Treatment Outcome Score, the two patient-reported instruments used in the pivotal trials, which have some use in documenting response but are research tools rather than clinical ones
- •An attack diary recording frequency, location, severity and treatment, which is what determines whether a patient needs long-term prophylaxis rather than on-demand treatment alone
When to Test
Diagnosis is confirmed before any on-demand drug is prescribed, using C4, C1-INH antigen and C1-INH function. For each dose, the monitoring window that matters is the first hour, when every case of anaphylaxis in the clinical programme occurred. Response is assessed at four and 24 hours, matching the trial endpoints, and a second 30 mg dose may be given within that 24 hours if the attack persists.
Interpretation & Notes
The honest framing is that there is nothing to monitor about the drug and everything to monitor about the patient. Ecallantide has no therapeutic level, no biomarker of effect in routine use, and a two-hour half-life, so the laboratory contributes nothing once the diagnosis is established. What it has instead is a one-hour window in which a dangerous and unpredictable reaction may begin, with symptoms that mimic the disease being treated. The diagnostic workup deserves emphasis for a separate reason: hereditary angioedema is commonly mistaken for allergic angioedema, sometimes for years, and patients are given adrenaline and steroids that cannot work. C4 is low between attacks as well as during them in most patients, which makes it a usable screening test, but the diagnosis needs both the antigenic and the functional C1-INH assay, because type II disease produces normal levels of a protein that does not work.
Common Questions
Why can't patients inject it themselves?
Because of anaphylaxis, and because the symptoms of anaphylaxis overlap almost exactly with the symptoms of the attack being treated. Across 255 hereditary angioedema patients in the clinical programme, 4% experienced anaphylaxis — 3% among the 187 who received it subcutaneously. A detailed review of the cases found all eight that met formal criteria occurred within an hour of dosing, none on first exposure, and all had cutaneous features typical of type I hypersensitivity. The boxed warning requires administration by a healthcare professional with the means to manage both anaphylaxis and the angioedema itself, precisely because throat swelling, wheezing and hypotension could be either. This is the drug's defining practical limitation: every other on-demand treatment for this disease — icatibant, C1-inhibitor concentrates, recombinant human C1-INH, and now oral sebetralstat — can be taken at home.
How does it differ from icatibant?
They interrupt the same pathway one step apart. Ecallantide inhibits plasma kallikrein, the enzyme that generates bradykinin, so it stops bradykinin being made. Icatibant is a bradykinin B2 receptor antagonist, so it stops bradykinin that already exists from signalling. In practice the differences that matter are not mechanistic: icatibant is a single self-administered injection, ecallantide is three injections given by a clinician; icatibant has no anaphylaxis boxed warning; and ecallantide is a 60-amino-acid recombinant protein produced in yeast, which is a plausible reason for its immunogenicity, while icatibant is a decapeptide. There has never been a head-to-head trial, and a 2026 systematic review of all twelve randomised trials in this space concluded that differences in design, attack severity thresholds, censoring rules and endpoint instruments make cross-trial comparison unreliable.
Why was it never approved in Europe?
The application was withdrawn rather than refused. Dyax filed with the EMA on 1 June 2010 and notified the CHMP on 11 November 2011 that it was withdrawing, at day 181 of the evaluation. The company said it did not have the data to resolve the committee's outstanding questions, and the stated concerns were the higher rate of hypersensitivity reactions seen in treated patients and whether the proposed dose was adequate in heavier patients. Dyax indicated it might resubmit on the basis of a bioequivalence study of a higher-strength single-millilitre formulation; no resubmission followed. Ecallantide remains a United States-only drug, which is why European guidelines and reviews of hereditary angioedema treatment list it with that qualifier attached.
Is it still available?
Yes, as of late 2026, though its practical role has narrowed considerably. Kalbitor remains listed in Drugs@FDA under BLA 125277 as a prescription product, the National Drug Code listing is active with Takeda Pharmaceuticals America as labeller, and the prescribing information was last revised in July 2025 — all signs of a product still being maintained. What has changed is the surrounding landscape. US guidelines since 2013 have recommended treating every attack as early as possible regardless of location or severity, which favours therapies a patient can carry; sebetralstat, an oral plasma kallikrein inhibitor hitting the same target as ecallantide, was approved in July 2025. A drug requiring a trip to a clinician fits that framework poorly.
What does the 'Kunitz domain' in its description mean?
It is the structural scaffold the molecule was built on. Kunitz domains are small, disulfide-stabilised protein folds that inhibit serine proteases — aprotinin is the classic example. Ecallantide was engineered from the first Kunitz domain of human lipoprotein-associated coagulation inhibitor, the protein now generally called tissue factor pathway inhibitor. Starting from that human scaffold, Dyax used phage display to vary the residues around the protease-contact loop and select variants that bound plasma kallikrein tightly and selectively, reaching an inhibition constant of 40 picomolar in the 1996 paper describing the work and 25 picomolar in the final drug. Building from a human sequence was meant to limit immunogenicity, which makes the 4% anaphylaxis rate a sobering result — though the drug is expressed in yeast, and antibody testing against either ecallantide or Pichia pastoris was not reliably positive in the patients who reacted.
Who Ecallantide Is NOT For
- •Known clinical hypersensitivity to ecallantide — the only absolute contraindication, and the reason it is stated twice on the label.
- •Administration in any setting without immediate capacity to manage anaphylaxis, which the boxed warning treats as a condition of use rather than a precaution.
- •Self-administration or home use of any kind, which has never been approved for this product.
- •Children under 12, in whom safety and effectiveness have not been established, though published case series describe use in younger patients.
- •Hepatic or renal impairment is not a formal contraindication but no pharmacokinetic data exist in either, so the dose has no evidential basis in those patients.
- •Pregnancy and breastfeeding, where the available information is a published safety review of hereditary angioedema medications rather than a study of this drug.
Drug & Supplement Interactions
No formal drug interaction studies were performed and no in vitro metabolism studies were done, which the label states plainly. For a 7,054-dalton protein cleared renally with a two-hour half-life, the usual mechanisms of pharmacokinetic interaction — cytochrome P450 competition, transporter inhibition, protein-binding displacement — are not where the risk lies. The considerations that do matter are pharmacodynamic and situational. Combining ecallantide with another on-demand hereditary angioedema treatment in the same attack has no evidence behind it and is not an approved strategy; the trials permitted rescue medication and censored those patients rather than studying combinations. Patients on long-term prophylaxis with a C1-inhibitor concentrate, lanadelumab or berotralstat may still have breakthrough attacks requiring on-demand treatment, and there is no reason to expect an adverse interaction, but neither is there a trial. The one interaction worth thinking about carefully is with the management of anaphylaxis itself. Because a hypersensitivity reaction to ecallantide looks very much like the attack it was given for, and because adrenaline, antihistamines and corticosteroids do not work on bradykinin-mediated angioedema, a clinician facing deterioration after dosing is in a genuinely ambiguous position — which is the entire reason the drug must be given where both conditions can be treated. Patients on beta-blockers, in whom anaphylaxis can be harder to reverse with adrenaline, deserve particular attention; this is a general principle rather than a documented ecallantide interaction, but it is the relevant one.
Safety Profile
Common Side Effects
Cautions
- • Anaphylaxis is the boxed warning. It occurred in 4% of 255 treated patients overall and 3% of the 187 given subcutaneous drug, always within the first hour and never on first exposure.
- • The symptoms of a hypersensitivity reaction and the symptoms of a hereditary angioedema attack are nearly indistinguishable — chest discomfort, flushing, pharyngeal oedema, wheezing, hypotension — which is why the label insists on close monitoring by someone equipped to treat both.
- • Administration must be by a healthcare professional with the means to manage anaphylaxis. There is no home-use pathway.
- • The drug is contraindicated outright in anyone with known clinical hypersensitivity to it.
- • IgE antibody testing against ecallantide or against Pichia pastoris was not consistently positive in patients who had reactions, so a negative antibody test does not identify who is safe.
- • Patients should be observed for an appropriate interval after dosing, taking into account that reactions in trials began within an hour.
- • Safety and effectiveness below age 12 have not been established, though a published series has described use in younger children.
- • No pharmacokinetic data exist in hepatic or renal impairment.
What We Don't Know
Who reacts, and why. Anaphylaxis never occurred on first exposure, which points to sensitisation, yet antibody testing against the drug and against its yeast expression system was inconsistent in exactly the patients who reacted — so the mechanism is unresolved and there is no pre-treatment test that identifies risk. Beyond that: whether the drug has any advantage over newer agents in laryngeal attacks specifically, where the evidence is a pooled analysis rather than a dedicated trial; how it behaves in pregnancy, where the data amount to a safety review rather than a study; whether the dose is adequate in heavier patients, a question the CHMP raised in 2011 and which was never formally answered; and what its place is now that an oral inhibitor of the same enzyme exists.
Legal Status
United States
FDA-approved and, as of late 2026, still marketed. Kalbitor was approved on 1 December 2009 under BLA 125277 for acute attacks of hereditary angioedema in patients 12 years and older. It carries a boxed warning for anaphylaxis and may be administered only by a healthcare professional with the means to manage anaphylaxis and angioedema. Drugs@FDA lists it as a prescription product, the National Drug Code listing is active with Takeda Pharmaceuticals America as labeller, and the prescribing information was last revised in July 2025. It is not a controlled substance.
International
Not authorised anywhere outside the United States. Dyax filed a centralised marketing authorisation application with the EMA on 1 June 2010 and withdrew it on 11 November 2011 at day 181 of the evaluation, stating it lacked the data to resolve the CHMP's outstanding questions; the committee's concerns were the higher rate of hypersensitivity reactions in treated patients and the adequacy of the proposed dose in heavier patients. A resubmission based on a higher-strength formulation was mentioned at the time but never filed. Reviews of hereditary angioedema therapy accordingly describe ecallantide as a United States-only option.
Sports & Competition
Not prohibited. Ecallantide appears nowhere on the WADA 2027 Prohibited List and no class reaches it — plasma kallikrein inhibitors are not covered by any substance category, and the drug has no plausible performance application, since it treats an acute episode of a rare genetic swelling disorder. The only consideration is procedural: it is given as three injections totalling 3 mL, far below the 100 mL per 12 hours threshold in prohibited method M2.2, and would in any case be administered during legitimate medical treatment.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Ecallantide is interchangeable with icatibant or C1-inhibitor concentrate because all three treat hereditary angioedema attacks.
Reality
They differ in mechanism, in route, and most consequentially in who can give them. Ecallantide inhibits plasma kallikrein; icatibant blocks the bradykinin B2 receptor; C1-inhibitor concentrates replace the missing protein upstream of both. Ecallantide is the only one of them that carries a boxed warning for anaphylaxis and the only one that cannot be taken at home. Since July 2025 there is also an oral option, sebetralstat, hitting the same enzyme as ecallantide. No head-to-head trial has ever compared any of them.
Myth
Adrenaline, antihistamines and steroids are a reasonable fallback if the specific drug is unavailable.
Reality
They are not, because the mediator is wrong. Hereditary angioedema attacks are driven by bradykinin, not histamine, so the entire allergy toolkit acts on a pathway that is not the one causing the swelling. This is more than an academic point: it is why patients are repeatedly misdiagnosed in emergency departments, and it is also why a hypersensitivity reaction to ecallantide is so dangerous — the clinician must distinguish two conditions with overlapping symptoms and opposite treatments.
Myth
A human-derived protein scaffold should not cause allergic reactions.
Reality
Ecallantide is the counterexample. It was deliberately engineered from a human Kunitz domain partly to limit immunogenicity, and it still produced anaphylaxis in about 4% of treated patients. The sequence was varied at up to nine positions during selection, it is expressed in yeast rather than in human cells, and the resulting molecule is novel even though its parent was not. Antibody testing in the patients who reacted was inconsistent, so even the mechanism remains uncertain.
Myth
The pivotal trials showed ecallantide resolves attacks quickly.
Reality
They showed patients rated their symptoms and their response better at four hours. Both primary endpoints were patient-reported composites — mean symptom complex severity score and treatment outcome score — and in EDEMA3 the more concrete endpoint, estimated time to significant improvement, was 165 minutes versus more than 240 on placebo and did not reach significance. A 2026 systematic review of all twelve randomised on-demand trials in this disease found six different instruments used to measure essentially the same thing, with censoring rules that differ between studies.
Myth
Kalbitor was withdrawn from the market.
Reality
It was withdrawn in Europe before it was ever approved there, which is a different thing. Dyax pulled its EMA application in November 2011 at day 181. In the United States the product remains listed in Drugs@FDA, its National Drug Code entry is active with Takeda as labeller, and the prescribing information was revised as recently as July 2025. What has happened is displacement rather than withdrawal: a drug requiring a clinician fits poorly with guidelines that ask patients to treat every attack immediately.
Published Research
29 studiesDiverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks
Tachdjian R et al., Advances in Therapy 2026. Reviews all twelve randomised trials of on-demand hereditary angioedema treatment and concludes they cannot sensibly be compared: eleven were centre-based and required presentation within five to eight hours of onset while one was home-based with immediate treatment, producing median times to treatment of 215–630 minutes versus 35–51. Eight trials used time to onset of symptom relief as the primary endpoint, measured by six different instruments, and placebo-arm censoring exceeded 50% in some.
Sebetralstat (Ekterly) for treatment of hereditary angioedema attacks
Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines
Cohn DM et al., J Allergy Clin Immunol 2025. Explains how the field moved: early guidelines gated treatment by attack location and severity, and the pivotal trials of ecallantide, icatibant and the C1-inhibitor products were designed to match. The 2013 US Hereditary Angioedema Association guidance then recommended treating every attack as early as possible — a shift that reshaped later trial design and left therapies requiring a clinic visit poorly aligned with the standard of care. The paper also notes ecallantide's United States-only status.
Extension of the circulatory half-life of recombinant ecallantide via albumin fusion without loss of anti-kallikrein activity
Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks
Design, expression and biological evaluation of DX-88mut as a novel selective factor XIa inhibitor for antithrombosis
Safety of medications for hereditary angioedema during pregnancy and lactation
Treatment of Hereditary Angioedema
Ecallantide: An alternative treatment of refractory angioedema in adolescents with systemic lupus erythematosus
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks
Craig TJ et al., J Allergy Clin Immunol Pract 2015. A retrospective review of the whole clinical database: 8 of 230 subcutaneously treated patients (3.5%) across 1,045 doses met NIAID criteria for anaphylaxis, none on first exposure, all within an hour, all with cutaneous features and all resolving with standard management. The uncomfortable finding is that IgE testing against ecallantide or against Pichia pastoris was not consistently positive in those patients, so there is no test that identifies who will react.
Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial
Lewis LM et al., Annals of Emergency Medicine 2015. A clean negative in a condition where the same mediator is implicated: 85%, 89% and 89% of patients on 10, 30 and 60 mg met discharge criteria within six hours against 72% on placebo plus conventional therapy, a non-significant difference, and the trial was halted at interim analysis. The authors' conclusion is the useful one — most emergency-department patients with mild to moderate ACE-inhibitor angioedema improve within six hours regardless of what is given.
Drugs derived from phage display: from candidate identification to clinical practice
Nixon AE, Sexton DJ and Ladner RC, MAbs 2014. Places ecallantide in context as one of the small number of approved drugs that came out of phage display rather than from immunisation or natural-product chemistry, written by people who were there for it.
Use of ecallantide in pediatric hereditary angioedema
Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks
Sheffer AL et al., Ann Allergy Asthma Immunol 2013. Laryngeal attacks are the ones that kill, and they were a minority of the trial population — 24 of 143 patients in the pivotal programme. This pooled analysis is the best available evidence for that subgroup, which is to say it is pooled, partly open-label and not powered as a trial of its own.
Analysis of hereditary angioedema attacks requiring a second dose of ecallantide
Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study
Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency
Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema
Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics
Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials
Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies
Sheffer AL et al., J Allergy Clin Immunol 2011. Pools EDEMA3 and EDEMA4, which is how the drug's efficacy is usually cited. Worth reading alongside the individual trials rather than instead of them — the pooled estimate is more precise but inherits both studies' reliance on patient-reported composite scales.
Response time for ecallantide treatment of acute hereditary angioedema attacks
Ecallantide for the treatment of acute attacks in hereditary angioedema
Cicardi M et al., NEJM 2010 (EDEMA3). 72 patients randomised to 30 mg subcutaneous ecallantide or placebo during an acute attack. The primary endpoint, treatment outcome score at four hours, favoured ecallantide (median 50.0 versus 0.0, p=0.004), as did the change in mean symptom complex severity score. The detail that rarely gets quoted is the third result: estimated time to significant improvement was 165 minutes versus more than 240, and that comparison was not significant at p=0.14.
Ecallantide: in acute hereditary angioedema
EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema
Levy RJ et al., Ann Allergy Asthma Immunol 2010. The second pivotal trial, 96 patients. Mean symptom complex severity score fell 0.8 versus 0.4 on placebo (p=0.01) and the treatment outcome score was 53.4 versus 8.1 (p=0.003), with benefit apparent by two hours and maintained to 24.
Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability
Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin
Markland W, Ley AC and Ladner RC, Biochemistry 1996. The origin paper. Phage-display libraries built from the first Kunitz domain of human lipoprotein-associated coagulation inhibitor were varied around the protease-contact loop and selected against plasma kallikrein, yielding EPI-K503 with a Ki of 40 picomolar and high specificity — the direct ancestor of ecallantide.
KALBITOR (ecallantide) injection — US Prescribing Information
Dyax s.a. withdraws its marketing authorisation application for Kalbitor (ecallantide) — EMA
Quick Facts
- Class
- Plasma Kallikrein Inhibitor (Kunitz Domain)
- Tier
- C
- Evidence
- Strong
- Safety
- Moderate Data
- Updated
- Oct 2026
- Citations
- 29PubMed
Also known as
Tags
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.